Waters™

アプリケーションノート

Furosemide

Waters Corporation



This is an Application Brief and does not contain a detailed Experimental section.

Abstract

This application brief demonstrates analysis of furosemide.

Introduction

The compound analyzed in this study is furosemide (USP Tailing Factors - 1.30).

1. Furosemide

Experimental

HPLC Method

Column: Symmetry Shield RP $_{18}$, 4.6 x 150 mm, 5 μm

Part number: 186000109

Mobile phase: 20 mM phosphate buffer, pH 7.0/acetonitrile


75:25

Flow rate: 1.0 mL/min

Injection volume: $5 \mu L$

Detection: UV @ 220 nm

Results and Discussion



Featured Products

WA31763.88, June 2003

© 2021 Waters Corporation. All Rights Reserved.